Leuko Raises $5 Million Series A to Validate and Bring to Market Its Noninvasive White Blood Cell Monitoring Technology for Cancer Patients


BOSTON–(BUSINESS WIRE)–Leuko, an MIT startup developing PointCheckTM, the first solution to enable non-invasive home white blood cell (WBC) monitoring, today announced an initial closing of $5 million in its Series A round. The new funding from HTH VC, Good Growth Capital, IAG Capital Partners, Nina Capital and angel investors will accelerate Leuko’s clinical trials to gain regulatory approval in collaboration with leading cancer centers including Boston Medical Center and MD Anderson in the USA. and Dexeus and Hospital 12 de Octubre in Europe. Leuko will also continue its go-to-market and partnering activities with healthcare providers, medical device distributors and pharmaceutical companies.

“Low WBC levels are one of the most common, as well as one of the most devastating and expensive, side effects of cancer chemotherapy. Clinical data shows that up to one in six chemotherapy patients experience life-threatening infections and hospital readmissions that are directly related to low WBCs,” said Dr. Carlos Castro-Gonzalez, co-founder and CEO of Leuko. “At Leuko, we are working on a solution to help patients and providers prevent these readmissions and improve clinical outcomes by remotely monitoring WBC levels before infections occur.”

With Leuko, patients simply place their finger on an internet-connected PointCheckTM Device only 1 minute a day. The device measures the leukocyte values ​​without taking blood. The data is sent to the patient’s care team, who can triage the findings to help patients receive appropriate, preventive treatments under the direction of their doctor. The technology has demonstrated excellent diagnostic accuracy and home usability in recent peer-reviewed studies.

“We are excited to help Leuko scale and make this clinically validated solution available to millions of patients who can lead healthier lives through increased surveillance of their compromised immune system,” said Michele Gaiotto, CEO of HTH VC, who is responsible for the Company Leads Series A. “We believe Leuko is building a strong team and technology platform and are honored to support this worthy mission.”

Amy Salzhauer, Managing Partner of Good Growth Capital, who led the Company Series Seed, said, “We remain impressed with the potential value that PointCheck offersTM Platform achieved by integrating a proprietary remote monitoring technology into a product that can be used by unattended patients at home.”

About Leuko

Leuko is a startup that emerged from MIT and the Madrid M+Vision Consortium and was founded by Carlos Castro-Gonzalez, Ian Butterworth, Aurelien Bourquard and Alvaro Sanchez-Ferro. They are developing a platform technology, PointCheckTM, which combines optics and AI to make noninvasive blood testing easier, faster, and more accessible than cutting-edge solutions. With its first application, Leuko aims to improve clinical outcomes for >2 million cancer chemotherapy patients per year, reduce their chemotherapy-related hospitalizations by 50%, and save >$6 billion annually in healthcare costs. For more information, visit https://leuko.com/ or follow us on Twitter @leuko.

About HTHVC

HTH is a full-fledged investment and advisory firm investing alongside brilliant innovators dedicated to improving human health. Founded in 2020, HTH complements ZCube-Zambon Research Venture’s scouting and investing activities with direct participation in early-stage deep-tech startups dedicated to improving human life.

hthvc.com

About good growth capital

Good Growth Capital is an early-stage, minority-owned, majority-owned venture capital firm that funds transformative startups in sectors such as biomedical engineering, green technology and data science. Good Growth Capital and its funds meet both ESG and UNSDG impact targets.

goodgrowthvc.com





Source link

READ:  Marcus Neuroscience Institute Stroke Expert Comments on New Study Linking Stroke Risk to Blood Type